13 , 14 , 27 Our study, which included Haplo-HCT from a more contemporary cohort reflecting the current practice shift with the growing adoption of Haplo-HCT since 2013, demonstrates a significant trend in reducing the survival gap when using mismatched donors and establishes Haplo-HCT with PTCy as an acceptable approach in patients with myelofibrosis in need of an allograft.
← all excerpts
Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study.
1
—
—